focus -WSS

focus

author：leisure time 2025-09-06 06:06:58 - browse：62377

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Fauci’s Covid grilling leads GOP to weigh foreign research rules

WSS

How I ended up pumping milk in a bathroom stall at JPM 2024

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

New Medicare drug pricing powers could soon be upended in court

EU fines Illumina $475 million over Grail acquisition

Caregivers of transplant patients call for more support, training

The debate over Covid

focus

focus

hotspot

Walensky prepares to leave CDC — and Congress — behind

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Peter Hotez and the public health issue of online harassment

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Alkermes shareholders re

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Alkermes shareholders re

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Drug repurposing or repositioning? The language matters

New menopause drug shows promise in relief for hot flashes

explore

Companies helping big Covid

Idaho abortion case may prompt more restrictions in other states

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Generative AI mines health records to identify patients’ social needs

Health and fitness trackers are measuring the wrong things

explore

hotspot

hotspot

Wikipedia